Literature DB >> 2253336

Phenotypic and molecular biological analysis of human butyrylcholinesterase variants.

B N La Du1, C F Bartels, C P Nogueira, A Hajra, H Lightstone, A Van der Spek, O Lockridge.   

Abstract

Our laboratory has recently shown that several variant forms of human butyrylcholinesterase, associated with unusual sensitivity to succinylcholine, are caused by specific mutations within the structural DNA coding for this enzyme. Atypical (dibucaine-resistant) butyrylcholinesterase is caused by a point mutation at nucleotide position 209(GAT-- greater than GGT), which changes aspartate 70 to glycine. One fluoride-resistant variant family has a point mutation at nucleotide 728(ACG-- greater than ATG), which changes threonine 243 to methionine. Another type of fluoride-resistant variant has a point mutation at nucleotide 1169(GGT-- greater than GTT), which changes glycine 390 to valine. One type of silent phenotype is due to a frame-shift mutation at nucleotide position 351(GGT-- greater than GGAG). A polymorphic site at nucleotide position 1615 (GCA/ACA), coding for Ala/Thr, accounts for the quantitative K-variant, which causes an approximate one-third reduction of activity, if Thr occupies that position at codon 539. Examples are given to illustrate the advantages of using a combination of the new DNA analytical techniques, including: the use of allele-specific probes, with the standard serum cholinesterase phenotyping methods. More accurate typing of patients with certain variants is now possible; pedigree analysis will be aided by the improved methodology.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2253336     DOI: 10.1016/0009-9120(90)90187-y

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  8 in total

1.  DNA mutation associated with the human butyrylcholinesterase K-variant and its linkage to the atypical variant mutation and other polymorphic sites.

Authors:  C F Bartels; F S Jensen; O Lockridge; A F van der Spek; H M Rubinstein; T Lubrano; B N La Du
Journal:  Am J Hum Genet       Date:  1992-05       Impact factor: 11.025

2.  Factors affecting inter-individual variation in human plasma cholinesterase activity: body weight, height, sex, genetic polymorphism and age.

Authors:  A Brock; V Brock
Journal:  Arch Environ Contam Toxicol       Date:  1993-01       Impact factor: 2.804

3.  A new detection method for the K variant of butyrylcholinesterase based on PCR primer introduced restriction analysis (PCR-PIRA).

Authors:  K Shibuta; M Abe; T Suzuki
Journal:  J Med Genet       Date:  1994-07       Impact factor: 6.318

4.  Pseudo-cholinesterase polymorphism in Mazandaran province (North of Iran).

Authors:  Ebrahim Zabihi; Meisam Shabanzadeh; Sina Arabsheibani; Ali Akbar Moghadamnia; Mahmoud Baradaran
Journal:  Caspian J Intern Med       Date:  2012

5.  Proposed nomenclature for human butyrylcholinesterase genetic variants identified by DNA sequencing.

Authors:  B N La Du; C F Bartels; C P Nogueira; M Arpagaus; O Lockridge
Journal:  Cell Mol Neurobiol       Date:  1991-02       Impact factor: 5.046

6.  Comparison of cognitive functions between people with silent and wild-type butyrylcholinesterase.

Authors:  I Manoharan; A Kuznetsova; J D Fisk; R Boopathy; O Lockridge; S Darvesh
Journal:  J Neural Transm (Vienna)       Date:  2007-02-22       Impact factor: 3.850

7.  Biochemical and genetic analysis of butyrylcholinesterase (BChE) in a family, due to prolonged neuromuscular blockade after the use of succinylcholine.

Authors:  Daniel Fantozzi Garcia; Ticiano G Oliveira; Greice A Molfetta; Luiz V Garcia; Cristiane A Ferreira; Adriana A Marques; Wilson Araujo Silva
Journal:  Genet Mol Biol       Date:  2011-03-01       Impact factor: 1.771

Review 8.  Understanding the Psychological, Physiological, and Genetic Factors Affecting Precision Pain Medicine: A Narrative Review.

Authors:  Andrea Chadwick; Andrew Frazier; Talal W Khan; Erin Young
Journal:  J Pain Res       Date:  2021-10-08       Impact factor: 3.133

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.